The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC
Authors:
- 2 September 2025
- journal article
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (13) , 927-935
Abstract
To evaluate the myeloprotective effects, safety, and survival outcomes of trilaciclib in first-line chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China. A single-center, retrospective study was conducted with 120 ES-SCLC patients receiving chemotherapy plus immunotherapy between January 2020 and January 2024. Patients were divided into a trilaciclib group (n = 60) and a control group (n = 60). The groups were compared for chemotherapy-related adverse effects, efficacy (ORR, DCR), and survival (PFS, OS). Trilaciclib significantly reduced the incidence of grade 3-4 neutropenia (18.3% vs. 66.7%, p < 0.001), grade ≥ 3 anemia (13.3% vs. 33.3%, p = 0.010), and thrombocytopenia (10.0% vs. 26.7%, p = 0.018). Median PFS was significantly longer in the trilaciclib group (6.2 vs. 4.7 months, p = 0.0139, HR = 0.6238, 95%CI 0.4474-0.9826), but no significant difference was observed in OS (15.6 vs. 13.8 months, p = 0.2399, HR = 0.8053, 95%CI 0.5577-1.163). The ORR was similar between the two groups (73.3% vs. 63.3%, p = 0.239). Trilaciclib demonstrates myeloprotective benefits in first-line treatment of ES-SCLC, with significant reductions in chemotherapy-related myelosuppression and improvements in treatment adherence. Although PFS was improved, no significant differences in OS or ORR were observed, indicating the need for further research with larger sample sizes to confirm its clinical efficacy.Keywords
Funding Information
- Self-funded Project under the Key Research and Development Program of Cangzhou City (23244102170)
This publication has 21 references indexed in Scilit:
- Small Cell Lung CancerJAMA, 2025
- Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?Supportive Care in Cancer, 2024
- Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Lung Cancer, 2023
- Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and EtoposideJournal of Thoracic Oncology, 2022
- Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trialsCancer Medicine, 2021
- Trilaciclib: First ApprovalDrugs, 2021
- Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trialInternational Journal of Cancer, 2020
- Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid TumorsAdvances in Therapy, 2020
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic reviewSupportive Care in Cancer, 2016